Polysomnographic assessment of suvorexant in patients with probable Alzheimer's disease dementia and insomnia: a randomized trial.

Alzheimers Dement · 2020 · PMC7984350 · PMID 31944580

Europe PMC DOI

hedged sentence

0.0100

closest p · 0.2× alpha

0.0100

boldest claim

The sentences

nominally significantp < 0.01actually significant

The only exploratory PSG measure that showed a nominally significant difference from placebo was sleep efficiency ( p < 0.01), indicating greater sleep efficiency with suvorexant.

also in 7,732 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.